Application of Purified Botulinum Type A Neurotoxin to Treat Experimental Trigeminal Neuropathy in Rats and Patients with Urinary Incontinence and Prostatic Hyperplasia

Table 2

BPH Patient profiles and results after intraprostatic NTX treatment.

	Baseline	1 week	1 month	3 months	6 months	9 months	12 months
Number of patients	10	10	10	10	9	9	8
IPSS	23.8 ± 7.0	19.4 ± 9.3*	16.3 ± 10.3*	14.9 ± 8.2*	13.8 ± 7.5*	13.8 ± 7.6*	16.9 ± 7.3*
Storage	8.7 ± 4.8	7.2 ± 4.5	6.7 ± 5.4	5.3 ± 3.8*	4.4 ± 3.5*	5.4 ± 3.5*	5.2 ± 4.3*
Voiding	11.8 ± 3.4	9.5 ± 4.4	6.9 ± 5.0*	7.4 ± 4.8*	7.0 ± 4.2*	6.8 ± 4.5*	7.4 ± 4.6*
QOL score	5.2 ± 1.0	4.3 ± 1.6*	3.4 ± 1.6*	3.3 ± 1.8*	3.2 ± 1.6*	3.7 ± 1.4*	4.3 ± 1.5*
Qmax, mL/s	6.3 ± 3.1	5.5 ± 2.0	6.1 ± 2.6	8.8 ± 2.9*	6.8 ± 3.9	6.2 ± 2.2	7.2 ± 4.0
Residual urine (mL)	99.5 ± 94.5	84.9 ± 83.1	101.5 ± 97.0	65.3 ± 73.6*	52.9 ± 62.5*	86.3 ± 100	72.4 ± 58.2
Prostatic volume (mL)	47.8 ± 21.2	45.9 ± 22.3	40.2 ± 18.2*	39.2 ± 19.5*	40.2 ± 19.2*	42.9 ± 23.2	41.0 ± 17.0
PSA (ng/mL)	4.30 ± 3.0				3.75 ± 2.2		4.35 ± 2.8

*Compared with baseline, 𝑃<0.05.